FDA Accepts Priority Review Request for Tyvaso DPI

FDA Accepts Priority Review Request for Tyvaso DPI

297098

FDA Accepts Priority Review Request for Tyvaso DPI

The U.S. Food and Drug Administration (FDA) has accepted United Therapeutics’ application for a priority review of Tyvaso DPI, an experimental dry powder inhaled formulation of treprostinil, to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).  PAH is a condition in which the narrowing of the arteries that connect the heart to the lungs result in high blood pressure. PH-ILD refers to a group of conditions caused by significant…

You must be logged in to read/download the full post.